TARCEVA Drug Patent Profile

When do Tarceva patents expire, and when can generic versions of Tarceva launch?

Tarceva is a drug marketed by Osi Pharms and is included in one NDA.

The generic ingredient in TARCEVA is erlotinib hydrochloride. There are twenty-five drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the erlotinib hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tarceva

A generic version of TARCEVA was approved as erlotinib hydrochloride by RISING on June 11^th, 2014.

Summary for TARCEVA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	103
Clinical Trials:	428
Patent Applications:	1,830
Drug Prices:	Drug price information for TARCEVA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TARCEVA
What excipients (inactive ingredients) are in TARCEVA?	TARCEVA excipients list
DailyMed Link:	TARCEVA at DailyMed

See drug prices for TARCEVA

Recent Clinical Trials for TARCEVA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Butler University	Phase 1
Indiana University	Phase 1
Hala Fadda	Phase 1

See all TARCEVA clinical trials

Paragraph IV (Patent) Challenges for TARCEVA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TARCEVA	Tablets	erlotinib hydrochloride	25 mg	021743	1	2008-11-18

US Patents and Regulatory Information for TARCEVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Osi Pharms	TARCEVA	erlotinib hydrochloride	TABLET;ORAL	021743-001	Nov 18, 2004		DISCN	Yes	No
Osi Pharms	TARCEVA	erlotinib hydrochloride	TABLET;ORAL	021743-002	Nov 18, 2004		DISCN	Yes	No
Osi Pharms	TARCEVA	erlotinib hydrochloride	TABLET;ORAL	021743-003	Nov 18, 2004		DISCN	Yes	No

International Patents for TARCEVA

See the table below for patents covering TARCEVA around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	735	Quinazoline derivatives.
African Regional IP Organization (ARIPO)	9600788
Argentina	002723	COMPUESTOS DERIVADOS DE QUINAZOLINA Y PROCEDIMIENTO PARA PREPARARLOS, COMPUESTO INTERMEDIARIOS UTILES EN DICHO PROCEDIMIENTO, SU USO
Austria	205483
Austria	446955
Australia	3585499
Australia	5040696

Supplementary Protection Certificates for TARCEVA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0817775	300214	Netherlands		300214, 20150606, EXPIRES: 20200320
0817775	91209	Luxembourg		91209, EXPIRES: 20200321
0817775	SPC/GB06/008	United Kingdom		PRODUCT NAME: ERLOTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OR POLYMORPH THEREOF, IN PARTICULAR THE HYDROCHLORIDE SALT; REGISTERED: CH 5726601 20050321; CH 5726602 20050321; CH 5726603 20050321; UK EU/1/05/311/001 20050919; UK EU/1/05/311/002 20050919; UK EU/1/05/311/003 20050919
0817775	06C0010	France		PRODUCT NAME: ERLOTINIB HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: EU/1/05/311/001 20050919; FIRST REGISTRATION: LI - 57266 20050321
0817775	CA 2006 00006	Denmark
0817775	C00817775/01	Switzerland		FORMER REPRESENTATIVE: BOHEST AG, CH
0817775	SPC001/2006	Ireland		SPC001/2006: 20070817, EXPIRES: 20200320

TARCEVA (erlotinib) Market Dynamics and Financial Trajectory: Exclusivity, Patent/Generic Risk, and Revenue Outlook

Last updated: July 21, 2026

Executive summary: TARCEVA (erlotinib) revenue has moved from peak oncology adoption to sustained erosion as generic erlotinib entered. The market is now shaped by (1) patent and exclusivity end-state dynamics, (2) FDA substitutability and payer incentives driving price compression, and (3) oncology guideline shifts that reduced the addressable patient set for erlotinib monotherapy and earlier-line use. Commercial exposure today is driven primarily by remaining branded demand (where any persists), generic volume and pricing, and the extent of any continued specialty use under constrained formularies.

---

What is TARCEVA (erlotinib) and how has demand evolved?

Quick answer: TARCEVA is an oral EGFR tyrosine kinase inhibitor (TKI). Its demand peaked in metastatic non-small cell lung cancer (NSCLC) settings where EGFR mutation testing did not fully define treatment selection, and later narrowed as testing and competing targeted therapies changed prescribing patterns.

Which indications drove historical uptake

TARCEVA’s commercial history is tied to multiple NSCLC and pancreas label components across time, with key dynamics including:

• EGFR-mutated NSCLC patient identification increasing over time, with newer EGFR TKIs (and sequencing strategies) capturing share.
• Combination and post-progression treatment frameworks evolving, which reduced the incremental role of erlotinib relative to later-generation EGFR inhibitors.

How guideline and sequencing shifts affect market size

Market contraction is typically driven by:

• Earlier use of other EGFR TKIs for EGFR-mutated disease.
• Increased preference for regimens that align with contemporary outcomes data and molecular testing algorithms.
• Reduced tolerance for older tolerability profiles if newer agents offer improved efficacy and safety tradeoffs.

---

When did TARCEVA lose exclusivity and how did generic entry change the pricing curve?

Quick answer: Branded TARCEVA’s exclusivity has ended; generic erlotinib is broadly available in the U.S., driving sustained price compression and shifting “financial trajectory” from brand revenue to generic volume economics.

Exclusivity timeline at a high level

• Brand era: peak branded adoption period followed by steady decline as generics neared entry.
• Post-launch generic era: rapid branded revenue drop around effective generic substitution, then stabilization at a lower branded share if any remains.
• Long tail: ongoing low-cost competition with periodic supply dynamics and payer contract resets.

What drives payer behavior once generics exist

With generic erlotinib available, payer dynamics typically prioritize:

• Lowest net price during contract cycles.
• Substitution at pharmacy level where permitted and where formularies allow.
• Narrower clinical “brand preference” unless specific product-level issues exist.

---

What is the Orange Book status of TARCEVA and how many drug/product listings matter?

Quick answer: TARCEVA’s FDA reference-listed drug (RLD) and associated dosage forms appear in the Orange Book with multiple generic equivalents. The practical outcome for finances is broad therapeutic interchangeability and discounted acquisition costs versus any branded sourcing.

What Orange Book structure implies for revenue

For branded oncology drugs, the Orange Book state translates into:

• Strong generic substitution once approvals are in place.
• Risk that any residual branded demand becomes limited to constrained prescriber preferences, patient-specific tolerability cases, or out-of-contract settings.

Dosage form impact

TARCEVA historically has been sold as oral tablets in different strengths. Generic competition is strongest where:

• FDA-approved generic strengths match common prescribing strengths.
• Multiple ANDA manufacturers compete.
• Package-level supply is stable.

---

What patents protect TARCEVA (erlotinib) and how strong is the patent estate?

Quick answer: The relevant patent estate is largely matured and has been overtaken by generic availability. For business strategy, remaining value is less about blocking entry and more about navigating residual formulation, method-of-use, and secondary patent remnants that may or may not be enforceable.

Patent estate components that historically matter

Erlotinib and its commercial product typically implicate:

• Active ingredient (compound) patents (expired by now for mature products).
• Formulation patents (e.g., tablet composition, coatings, stability).
• Method-of-use patents (specific clinical regimens or biomarkers).
• Manufacturing/process patents (scale-up and solid oral manufacturing processes).

How patent coverage maps to revenue today

In mature drugs like TARCEVA:

• Compound patent expiry and initial exclusivity end dominate financial trajectory.
• Secondary patents can extend brand position only if (a) they are properly listed and (b) they are actively litigated or trigger exclusivity for specific ANDA pathways.

---

Which companies supply generic erlotinib and what does competition look like?

Quick answer: Generic erlotinib has broad market availability with multiple ANDA holders, creating a commodity-like pricing environment for most payer networks.

Competitive landscape effects on net pricing

As more manufacturers compete:

• Net price declines toward a low-cost band.
• Contracting shifts to volume-based terms and rebate structures.
• Brand manufacturers have limited leverage once interchangeability is established.

Supply and pricing volatility

Generic markets can still show periodic volatility from:

• Manufacturing capacity constraints.
• Quality system issues at plants.
• Short-term shortages that temporarily lift pricing or reduce substitution rates.

---

What generic entry risks existed for TARCEVA and what Paragraph IV challenges mattered?

Quick answer: In the TARCEVA lifecycle, the key financial inflection points are driven by generic ANDA approvals and effective substitution rather than ongoing Paragraph IV litigation for active revenue protection. That said, Paragraph IV events historically catalyze “brand-to-generic” revenue transitions.

How Paragraph IV typically affects timing

• Filing triggers 180-day exclusivity for the first Paragraph IV filer if qualifying.
• Settlements often include delayed entry dates or “pay-for-delay” constructs, though outcomes vary by case.
• Even after initial entry, additional ANDAs intensify erosion.

---

What patent litigation affects TARCEVA and how did settlements shift market timing?

Quick answer: The current financial landscape is consistent with completed entry and mature enforcement, meaning litigation outcomes that mattered commercially have already played out.

What litigation outcomes would have done to the financial trajectory

When present, settlements generally:

• Shift entry dates earlier or later.
• Define at-launch product design around method-of-use or formulation constraints.
• Influence the pace at which multiple ANDAs enter.

---

How does TARCEVA compare with competing EGFR inhibitors in financial and market dynamics?

Quick answer: Newer EGFR TKIs and sequencing practices have shifted the treatment mix away from erlotinib. This affects addressable volume even when generic pricing is low.

Substitution-by-therapy vs substitution-by-price

Two forces can operate simultaneously:

1. Price substitution: generics make erlotinib inexpensive.
2. Therapeutic substitution: clinicians choose newer EGFR agents with better outcomes and tolerability profiles.

For TARCEVA, the second force is a major driver of long-term volume dilution even after generics enter.

Segment-level effect

• EGFR-mutated lines: increasingly dominated by newer TKIs and regimen strategies.
• Post-progression: erlotinib can persist in certain practice patterns but competes with broader targeted options.

---

What FDA regulatory pathway changes matter for erlotinib’s market position?

Quick answer: With generic access established, the regulatory focus shifts to ANDA maintenance, label updates, and safety communications that influence prescribing and payer policies.

Practical FDA-linked levers affecting revenues

• Label updates that change patient selection can shrink eligible populations.
• Safety signals (e.g., dermatologic/toxicity management) influence adherence and persistence, which impacts real-world demand.
• Patent and exclusivity listings in the Orange Book influence the timing and structure of ANDA approvals.

---

How does manufacturing and formulation affect TARCEVA economics?

Quick answer: In generic markets, economics depend on bioequivalence, manufacturing cost, and supply stability more than on novel formulation IP.

What matters to buyers and payers in generic erlotinib

• Availability across common strengths.
• Low acquisition cost under contracts.
• Consistent dosing-form stability that reduces switching friction.

---

What is TARCEVA’s revenue trajectory: branded vs generic economics?

Quick answer: Branded TARCEVA revenue has declined materially and is now largely supplanted by generic volume. Remaining commercial value is concentrated in low-margin generic channel economics rather than high-margin brand revenue.

Revenue trajectory model for mature branded-once oncology drugs

A typical lifecycle pattern after generic entry:

• Pre-entry: rising/peak branded sales, driven by label breadth and uptake.
• Entry year: sharp branded decline around effective substitution; brand retains only small share.
• Post-entry: brand sales approach minimal residual levels; net revenue shifts to generic market pricing and volume.

Where financial value remains

Even without brand premium:

• Some practitioners may keep erlotinib in specific clinical niches.
• Payers may include low-cost generics consistently in formularies.
• EHR-linked persistence patterns can maintain baseline demand.

---

Key Takeaways

• TARCEVA’s financial trajectory is dominated by the post-exclusivity transition to generic erlotinib and the resulting shift from brand revenue to commodity-like pricing.
• Market demand has narrowed over time due to EGFR testing maturity and competing EGFR TKIs capturing treatment share.
• Patent litigation and Paragraph IV events historically shaped the timing of generic erosion, but today the commercial landscape reflects broad substitution and sustained price pressure.
• Remaining value is driven by generic coverage, contract pricing, and real-world persistence rather than renewed branded exclusivity.

---

FAQs

1) Does erlotinib still have meaningful clinical use despite newer EGFR TKIs?
Yes, in practice it retains use in some pathways, but competitive therapy substitution constrains the overall addressable market.

2) What drives net price for generic erlotinib more than patent factors?
Payer contracting, volume-based rebates, and competition among ANDA suppliers.

3) How do Orange Book listings influence access to generic erlotinib?
They determine whether certain patents can block or delay ANDA approvals and shape the litigation landscape around launch timing.

4) What role do safety/tolerability and persistence play in erlotinib market outcomes?
They influence adherence and discontinuation rates, which directly affect real-world demand even under low acquisition costs.

5) Are formulation or method-of-use patents a meaningful barrier for modern erlotinib entry?
For a mature product with widespread generic availability, barriers are typically limited to narrow, already-mature disputes; commercial impact is more limited than during initial exclusivity.

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. FDA Drug Label Information for TARCEVA (erlotinib).